ResearchMoz

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

GBI Research
Published Date » 2013-09-23
No. Of Pages » N/A
   
 GBI Research, the leading business intelligence provider, has released its latest research: Solid Tumors in Asia-Pacific Market to 2019 - New and Anticipated Approvals of Targeted Therapies to Trigger a Shift in Treatment Paradigm, which provides in-depth analysis of four key therapeutic indications within the Asia-Pacific (APAC) solid tumors market – bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer – covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these four solid tumor types.  
   
 The value...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Solid Tumors Market in Asia Pacific to 2019 - Introduction
2.1 Introduction

3 Solid Tumors Market in Asia Pacific to 2019 - Therapeutic Landscape
3.1 Bladder Cancer
3.1.1 Symptoms
3.1.2 Etiology
3.1.3 Pathophysiology
3.1.4 Diagnosis
3.1.5 Classification
3.1.6 Epidemiology
3.1.7 Prognosis and Disease Staging
3.1.8 Treatment Options
3.2 Ovarian Cancer
3.2.1 Symptoms
3.2.2 Etiology
3.2.3 Pathophysiology
3.2.4 Diagnosis
3.2.5 Classification
3.2.6 Epidemiology
3.2.7 Prognosis and Disease Staging
3.2.8 Treatment Options
3.3 Pancreatic Cancer
3.3.1 Symptoms
3.3.2 Etiology
3.3.3 Pathophysiology
3.3.4 Diagnosis
3.3.5 Classification
3.3.6 Epidemiology
3.3.7 Prognosis and Disease Staging
3.3.8 Treatment Algorithm
3.4 Prostate Cancer
3.4.1 Symptoms
3.4.2 Etiology
3.4.3 Pathophysiology
3.4.4 Co-Morbidities and Complications
3.4.5 Diagnosis
3.4.6 Classification
3.4.7 Epidemiology
3.4.8 Prognosis and Disease Staging
3.4.9 Treatment Options

4 Solid Tumors Market in Asia Pacific to 2019 - Marketed Products
4.1 Bladder Cancer
4.2 Ovarian Cancer
4.3 Pancreatic Cancer
4.4 Prostate Cancer
4.5 Key Marketed Products
4.5.1 Carboplatin
4.5.2 Cisplatin
4.5.3 Gemcitabine
4.5.4 Paclitaxel
4.5.5 Doxorubicin
4.5.6 Avastin (bevacizumab)
4.5.7 Tarceva (erlotinib)
4.5.8 Sutent (sunitinib)
4.5.9 Afinitor (everolimus)
4.5.10 Taxotere (docetaxel)
4.5.11 Zytiga (abiraterone acetate)
4.5.12 Jevtana (cabazitaxel)

5 Solid Tumors Market in Asia Pacific to 2019 - Pipeline Analysis
5.1 Bladder Cancer Pipeline
5.1.1 Overall Pipeline
5.1.2 Pipeline Analysis by Molecule Type
5.1.3 Pipeline Analysis by Mechanism of Action
5.2 Ovarian Cancer Pipeline
5.2.1 Overall Pipeline
5.2.2 Pipeline Analysis by Molecule Type
5.2.3 Pipeline Analysis by Mechanism of Action
5.3 Pancreatic Cancer Pipeline
5.3.1 Overall Pipeline
5.3.2 Pipeline Analysis by Molecule Type
5.3.3 Pipeline Analysis by Mechanism of Action
5.4 Prostate Cancer Pipeline
5.4.1 Overall Pipeline
5.4.2 Pipeline Analysis by Molecule Type
5.4.3 Pipeline Analysis by Mechanism of Action
5.5 Promising Drug Candidates in the Pipeline
5.5.1 Abraxane (albumin-bound paclitaxel)
5.5.2 AMG 386 (trebananib)
5.5.3 Votrient (pazopanib)
5.5.4 Xtandi (enzalutamide)

6 Solid Tumors Market in Asia Pacific to 2019- Market Forecast
6.1 Asia-Pacific Market
6.1.1 Treatment Usage Patterns
6.1.2 Annual Cost of Treatment
6.1.3 Market Size
6.2 India
6.2.1 Treatment Usage Patterns
6.2.2 Annual Cost of Treatment
6.2.3 Market Size
6.3 Australia
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Treatment
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Treatment
6.4.3 Market Size
6.5 Japan
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Treatment
6.5.3 Market Size
6.6 Drivers and Barriers for the Solid Tumors Market in APAC
6.6.1 Drivers
6.6.2 Barriers

7 Solid Tumors Market in Asia Pacific to 2019 - Deals and Strategic Consolidations
7.1 Deals Analysis
7.2 Major Co-Development Deals
7.2.1 ScinoPharm Taiwan and Coland Enter into Agreement to Develop Generic Oncological Drugs
7.2.2 Bind Biosciences Enters into Agreement with Amgen to Develop Cancer Drugs
7.2.3 Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug
7.2.4 Merck Serono Enters into Co-Development Agreement with Threshold Pharma for TH-302,
Pancreatic Cancer Drug
7.2.5 Seattle Genetics Exercises Option for Co-Development Agreement with Agensys (affiliate of
Astellas) for ASG-15ME
7.3 Major Licensing Deals
7.3.1 Spectrum Pharma Amends Licensing Agreement with Allergan for Apaziquone
7.3.2 Chugai Pharma Enters Into Licensing Agreement with Debiopharm Group for FF284
7.3.3 Baxter International Enters into Licensing Agreement with Onconova Therapeutics for
Rigosertib
7.3.4 Dyax Enters Into Licensing Agreement with Kadmon for Oncology Drug
7.3.5 Medigene Extends Licensing Agreement with Syncore for EndoTAG-1

8 Solid Tumors Market in Asia Pacific to 2019 - Appendix
8.1 Pipeline Drugs by Phase
8.1.1 Phase III
8.1.2 Pre-registration/NDA-filed
8.2 Market Forecasts to 2018
8.2.1 APAC
8.2.2 Australia
8.2.3 China
8.2.4 India
8.2.5 Japan
8.3 Market Definitions
8.4 Abbreviations
8.5 Sources
8.6 Research Methodology
8.6.1 Coverage
8.6.2 Secondary Research
8.6.3 Primary Research
8.6.4 Therapeutic Landscape
8.6.5 Geographical Landscape
8.6.6 Pipeline Analysis
8.7 Expert Panel Validation
8.8 Contact Us
8.9 Disclaimer

List of Tables


Table 1: Solid Tumors Market, Bladder Cancer, AJCC TNM Staging System, 2010
Table 2: Solid Tumors Market, Bladder Cancer, Treatment by Staging, 2013
Table 3: Solid Tumors Market, Ovarian Cancer, AJCC’s TNM and FIGO Staging Systems, 2013
Table 4: Solid Tumors Market, Pancreatic Cancer, AJCC TNM Staging System, 2013
Table 5: Solid Tumors Market, Prostate Cancer, AJCC Staging System, 2013
Table 6: Solid Tumors Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 7: Solid Tumors Market, Global, Pharmaceutical Pipeline (Pre-registration/NDA-filed), 2013
Table 8: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Market Forecast, 2012–2019
Table 9: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Market Forecast, 2012–2019
Table 10: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Market Forecast, 2012–2019
Table 11: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Market Forecast, 2012–2019
Table 12: Solid Tumors Market, Australia, Ovarian Cancer, Market Forecast, 2012–2019
Table 13: Solid Tumors Market, Australia, Bladder Cancer, Market Forecast, 2012–2019
Table 14: Solid Tumors Market, Australia, Pancreatic Cancer, Market Forecast, 2012–2019
Table 15: Solid Tumors Market, Australia, Prostate Cancer, Market Forecast, 2012–2019
Table 16: Solid Tumors Market, China, Ovarian Cancer, Market Forecast, 2012–2019
Table 17: Solid Tumors Market, China, Bladder Cancer, Market Forecast, 2012–2019
Table 18: Solid Tumors Market, China, Pancreatic Cancer, Market Forecast, 2012–2019
Table 19: Solid Tumors Market, China, Prostate Cancer, Market Forecast, 2012–2019
Table 20: Solid Tumors Market, India, Ovarian Cancer, Market Forecast, 2012–2019
Table 21: Solid Tumors Market, India, Bladder Cancer, Market Forecast, 2012–2019
Table 22: Solid Tumors Market, India, Pancreatic Cancer, Market Forecast, 2012–2019
Table 23: Solid Tumors Market, India, Prostate Cancer, Market Forecast, 2012–2019
Table 24: Solid Tumors Market, Japan, Ovarian Cancer, Market Forecast, 2012–2019
Table 25: Solid Tumors Market, Japan, Bladder Cancer, Market Forecast, 2012–2019
Table 26: Solid Tumors Market, Japan, Pancreatic Cancer, Market Forecast, 2012–2019
Table 27: Solid Tumors Market, Japan, Prostate Cancer, Market Forecast, 2012–2019

List of Figures


Figure 1: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Epidemiology, 2012–2019
Figure 2: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Superficial and Stage I, 2013
Figure 3: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Stage II and III, 2013
Figure 4: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Epidemiology, 2012–2019
Figure 5: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage I and II, 2013
Figure 6: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage III and IV, 2013
Figure 7: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Epidemiology, 2012–2019
Figure 8: Solid Tumors Market, Pancreatic Cancer, Treatment Algorithm, 2013
Figure 9: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Epidemiology, 2012–2019
Figure 10: Solid Tumors Market, Prostate Cancer, Treatment Algorithm, 2013
Figure 11: Solid Tumors Market, Global, Avastin, Annual Sales ($m), 2006–2013e
Figure 12: Solid Tumors Market, Global, Tarceva, Annual Sales ($m), 2006–2013e
Figure 13: Solid Tumors Market, Global, Sutent, Annual Sales ($m), 2006–2013e
Figure 14: Solid Tumors Market, Global, Afinitor, Annual Sales ($m), 2009–2013e
Figure 15: Solid Tumors Market, Global, Zytiga, Annual Sales ($m), 2011–2013e
Figure 16: Solid Tumors Market, Global, Jevtana, Annual Sales ($m), 2010–2013e
Figure 17: Solid Tumors Market, Global, Bladder Cancer, Pipeline, 2013
Figure 18: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Molecule Type, 2013
Figure 19: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Mechanism of Action, 2013
Figure 20: Solid Tumors Market, Global, Ovarian Cancer, Pipeline, 2013
Figure 21: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Molecule Type, 2013
Figure 22: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Mechanism of Action, 2013
Figure 23: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline, 2013
Figure 24: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Molecule Type, 2013
Figure 25: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Mechanism of Action, 2013
Figure 26: Solid Tumors Market, Global, Prostate Cancer, Pipeline, 2013
Figure 27: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Molecule Type, 2013
Figure 28: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Mechanism of Action, 2013
Figure 29: Solid Tumors Market, Asia-Pacific, Market Size ($m), 2012–2019
Figure 30: Solid Tumors Market, India, Market Size ($m), 2012–2019
Figure 31: Solid Tumors Market, Australia, Market Size ($m), 2012–2019
Figure 32: Solid Tumors Market, China, Market Size ($m), 2012–2019
Figure 33: Solid Tumors Market, Japan, Market Size ($m), 2012–2019
Figure 34: Solid Tumors Market, Global, Deals, 2006–2013
Figure 35: Solid Tumors Market, Global, Co-development Deals, 2006–2013
Figure 36: Solid Tumors Market, Global, Licensing Deals, 2006-2013
Figure 37: GBI Research Market Forecasting Model

Upcoming Reports:

Unconventional Natural Gas Extraction Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Natural gas obtained from coal, gas shale, and gas hydrates are generally referred to as unconventional natural gases. There has been a rapid growth in the exploration and production of unconventional natural gas due to the need for power generation. Technological improvements in the extraction methods like drilling and hydraulic fracturing and benefits of natural gas over other fuels for power generation are some important reasons driving this market.  Widespread availability of unconventional natural gas resources is also adding to their increasing use in the...
Poland: potatoes market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the potatoes market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the potatoes market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...
Smart Pills Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Smart pill technology is used to diagnose gastrointestinal (GI) disorders such as constipation and gastroparesis. Smart pill technology functions by providing the practitioner, with information pertaining to various parameters such as pH, temperature and pressure of gastrointestinal tract. This technology comprises wireless capsule, a receiver worn (by the patient) and computer software that analyzes and sorts the collated information. Smart pill is a nascent technology that holds immense potential in the field of medical diagnostics. The etiology for some of the gastrointestinal disorders...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
Samsung Records Poorest Profits in Q3 2014
Oct 29, 2014  
In the quarter ending September 2014, Samsung Electronics Co. Ltd registered the smallest earnings ever in two years. The drop in earnings can be easily attributed to heavy competition from new Chinese devices and the Apple phones. The net income stood at US$4 billion for the South Korea-based company. Apple has been Samsung’s strongest contender ever since the latter entered the...